Answers are grounded in this paper and cite their sources.
Combination therapy with GSK-3β inhibitor 9-ING-41 and venetoclax shows proof-of-concept in double-hit lymphoma, suggesting further preclinical investigations are warranted.
The demonstrated single-agent efficacy and combination synergy with venetoclax support the potential of 9-ING-41 as a novel therapeutic strategy for DHL. These findings provide a proof-of-concept that may serve as a basis for future preclinical investigations in DHL.
No takes yet. Share an insight, caveat, or question.
Lei et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: